BlackfinBio Limited has received approval from the FDA to trial a novel therapy for Hereditary Spastic Paraplegia ...

Metsera is a new GLP-1 player with a Phase 2b injectable and promising oral and amylin drugs in development. Learn why MTSR ...

Researchers have observed a decline in industry-sponsored post-approval clinical trials since the Inflation Reduction Act (IRA) was passed.

Q1 2025 Management View CEO Shankar Musunuri highlighted advancements in Ocugen’s modifier gene therapy platform, specifically targeting three biologics license application (BLA) filings over the next ...

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen's senior management team will host the call, which ...

SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy ...

PMV Pharma ended the first quarter with $165.8 million in cash, cash equivalents, and marketable securities, compared to $183.3 million as of December 31, 2024. Net cash used in operations was $18.3 ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials ...

Q2 2025 Management View CEO Mitchell Steiner emphasized Veru’s focus on its obesity program, highlighting the positive Phase 2b clinical trial results for enobosarm. This drug, when combined with ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...